These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
767 related articles for article (PubMed ID: 18665754)
1. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Ballova V; Ladicka M; Vranovsky A; Lakota J Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754 [TBL] [Abstract][Full Text] [Related]
3. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
5. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756 [TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144 [TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724 [TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476 [TBL] [Abstract][Full Text] [Related]
9. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540 [TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Puig N; Pintilie M; Seshadri T; al-Farsi K; Franke N; Keating A; Kuruvilla J; Crump M Bone Marrow Transplant; 2011 Oct; 46(10):1339-44. PubMed ID: 21243027 [TBL] [Abstract][Full Text] [Related]
11. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837 [TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639 [TBL] [Abstract][Full Text] [Related]
13. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115 [TBL] [Abstract][Full Text] [Related]
14. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469 [TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis. Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707 [TBL] [Abstract][Full Text] [Related]
16. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases]. Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021 [TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354 [TBL] [Abstract][Full Text] [Related]
18. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Morschhauser F; Brice P; Fermé C; Diviné M; Salles G; Bouabdallah R; Sebban C; Voillat L; Casasnovas O; Stamatoullas A; Bouabdallah K; André M; Jais JP; Cazals-Hatem D; Gisselbrecht C; J Clin Oncol; 2008 Dec; 26(36):5980-7. PubMed ID: 19018090 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949 [TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]